comprehensive -WSS

comprehensive

author：explore 2025-09-30 23:40:42 - browse：43116

A sign of Elevance Health behind some flowers — coverage from STAT — Michael Conroy/AP

Paul Marchetti, the head of insurer Elevance Health’s pharmacy benefit manager, has left the company amid a wave of consumer complaints about patients receiving incorrect medicines or being unable to get their prescriptions filled.

Elevance did not confirm Marchetti’s departure as the president of CarelonRx, but according to his Linkedin profile, he left the company in May.

Elevance, the second-largest commercial health insurer in the country by market share, uses its CarelonRx subsidiary to manage its pharmacy business. In online complaints, CarelonRx customers point toward January 1 as the date when issues with obtaining their prescriptions from the company began. The reported problems include safety issues like receiving other people’s medications or receiving medications they discontinued years ago.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Oral obesity drug from Viking Therapeutics hits key early target

leisure time

WSS

Republican states more likely to report Covid vaccine side effects

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Harvard's David Sinclair gets blowback over aging

Why Talkspace is targeting Medicare, a tricky market

Bird flu in dairy cattle: New measures to control spread to humans

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Longer MASH drug regimen improved liver, Akero study finds

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Longer MASH drug regimen improved liver, Akero study finds

At least 13 dead in Texas as scorching temps continue

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

DIEP, the 'gold standard' of breast reconstruction, is under threat

He's 19 months old and has one of the world’s rarest diseases

Bright Health sells Medicare Advantage business to Molina

Medicare drug price negotiation continues, as pharma counteroffers

focus

The untold story of TV’s first prescription drug ad

Lack of health data on LGBTQ+ people has serious consequences

State of the Union pitch: Bigger Medicare drug price negotiations

Medicare drug price negotiation continues, as pharma counteroffers

Multiple sclerosis has subtypes with different best treatments: study

$1 billion proposal to grow Boston, Massachusetts biotech

Wikipedia

explore

leisure time

leisure time